For the Inventor, By the Inventor

Enter assignee name

Alameda, CA, United States of America

Glycomed, Inc.

USPTO Granted Patents = 56

Forward Citations = 1,411

Loading Chart...

Loading Chart...

54 inventors (with patents filed for the assignee):

John H Musser (23 out of 113 patents)

Brian K Brandley (14 out of 14 patents)

Narasinga Rao (12 out of 12 patents)

4. Mark Brian Anderson (11 out of 17 patents)

5. Kevin R Holme (10 out of 11 patents)

6. Michael Tiemeyer (10 out of 10 patents)

7. Falguni Dasgupta (8 out of 8 patents)

8. Daniel E Levy (7 out of 7 patents)

9. Peng Cho Tang (6 out of 118 patents)

10. Margaret Moreland (6 out of 17 patents)

11. Hans Schweingruber (6 out of 6 patents)

12. Stuart J Swiedler (6 out of 7 patents)

13. Saeed A Abbas (6 out of 6 patents)

14. Richard E Galardy (4 out of 9 patents)

15. Darwin S Asa (4 out of 4 patents)

Core Competencies:

Matrix Metalloprotease Inhibitors

Triterpenoid Acid Derivatives

Sialyl Lewis Mimetics

Oligosaccharide Glycosides

Cell Adhesion Inhibitors

Heparin Derivatives

Glycopeptides

Anti-Inflammatory Agents

Sulfated Polysaccharides

Selectin Binding Compounds

Sialic Acid Medicaments

Carbohydrate Synthesis

56 patents: Sort by Forward Citations

1. 5892112 - Process for preparing synthetic matrix metalloprotease inhibitors (1999-04-06),

2. 5874411 - Oligosaccharide glycosides having mammalian immunosuppresive and (1999-02-23),

3. 5849709 - Saccharopeptides and derivatives thereof (1998-12-15),

4. 5837690 - Derivatives of triterpenoid acids and uses thereof. (1998-11-17),

5. 5837689 - Sialyl lewis-x mimetics containing naphthyl backbones (1998-11-17),

6. 5808021 - Method for controlling O-desulfation of heparin (1998-09-15),

7. 5795958 - Library of glyco-peptides useful for identification of cell adhesion (1998-08-18),

8. 5795875 - Therapeutic methods of using O-desulfated heparin derivatives (1998-08-18),

9. 5789385 - Sialyl Lewis.sup.x mimetics containing phenyl backbones (1998-08-04),

10. 5773438 - Synthetic matrix metalloprotease inhibitors and use thereof (1998-06-30),

11. 5763582 - Derivatives of triterpenoid acids and uses thereof (1998-06-09),

12. 5750508 - Sialic acid/fucose based medicaments (1998-05-12),

13. 5739115 - Sulfated maltooligosaccharides with heparin-like properties (1998-04-14),

14. 5728685 - Methods of treating inflammation using cell adhesion inhibitors (1998-03-17),

15. 5696147 - Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors (1997-12-09),

Glycomed, Inc. is a leading biotechnology company specializing in the research, development, and commercialization of therapeutic products. With a focus on innovative solutions, Glycomed aims to improve patients' lives by addressing unmet medical needs. Our dedicated team of scientists and experts is committed to delivering high-quality treatments for various diseases, including metabolic disorders, autoimmune conditions, and oncology. Through cutting-edge technologies, strategic partnerships, and a strong pipeline of products, Glycomed is at the forefront of advancing healthcare.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

56 Patents

#9 in Alameda, CA

#1,447 in California

#6,137 in US

#12,355 in the World

Alameda, CA, United States of America

Glycomed, Inc.

Forward Citations = 1,411

54 inventors:

John H Musser (23 out of 113 patents)

Brian K Brandley (14 out of 14 patents)

Narasinga Rao (12 out of 12 patents)

4. Mark Brian Anderson (11 out of 17 patents)

5. Kevin R Holme (10 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…